- Home
- SDHY vs NPCE Comparison
SDHY vs NPCE Comparison
Compare SDHY & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDHY | NPCE |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.2M | 328.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SDHY | NPCE |
|---|---|---|
| Price | $16.42 | $16.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.29 |
| AVG Volume (30 Days) | 94.0K | ★ 248.7K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | N/A | ★ $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | N/A | $1.28 |
| P/E Ratio | $14.31 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $13.93 | $7.56 |
| 52 Week High | $15.50 | $18.98 |
Technical Indicators
Market Signals| Indicator | SDHY | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 62.47 |
| Support Level | $16.36 | $16.00 |
| Resistance Level | $16.58 | $16.94 |
| Average True Range (ATR) | 0.14 | 0.80 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 38.10 | 68.23 |
Price Performance
Historical ComparisonAbout SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.